Featured News
(PMLiVE [UK]) Jan 19, 2021 - GlaxoSmithKline’s dostarlimab – an investigational PD-1 inhibitor – has demonstrated promising results in patients with heavily pre-treated solid cancer tumours.
The updated data comes from cohort F of...
(OBR) Jan 17, 2021 - Ivosidenib added nearly three months to the median overall survival of previously treated patients with advanced IDH1-mutated cholangiocarcinoma (CCA), compared with placebo, according to findings reported at the...
(OBR) Jan 17, 2021 - Preoperative neoadjuvant modified FOLFIRINOX is associated with favorable overall survival (OS) rates in patients with borderline resectable pancreatic cancer, relative to historical data. But combining this therapy...
(Agios) Jan 17, 2021 - Agios Pharmaceuticals, Inc. today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib tablets) in patients with...
(MedPage Today) Jan 16, 2021 - Patients with untreated advanced gastric or gastroesophageal junction (GEJ) cancer lived longer without disease progression with the addition of a fibroblast growth factor receptor (FGFR) inhibitor to...
More News
(Eisai) Jan 27, 2021 - Data will include a late-breaking oral presentation from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) (NCT02811861) (Abstract # 269) evaluating KEYTRUDA plus LENVIMA and LENVIMA plus everolimus versus...
(Medscape Medical News) Jan 25, 2021 - Combining an EGFR inhibitor with a pair of checkpoint inhibitors can produce 'promising' activity in certain patients with colorectal cancer, according to an investigator from a phase 2 trial.
(Yahoo! Finance) Jan 20, 2021 – RenovoRx today announced two research studies were presented at the 2021 ASCO Gastrointestinal Cancers Symposium that further advance the science of pancreatic cancer treatment.
(GSK) Jan 16, 2021 - GlaxoSmithKline plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid cancers being presented today at the 2021 American Society of...
(Evaluate Vantage) Jan 18, 2021 - Enhertu’s additional approval this morning for Her2-positive gastric cancer coincided with the Asco-GI conference, which featured a front-line gastric cancer study of Five Prime’s bemarituzumab as a...
(The Center For Biosimilars) Jan 18, 2021 - Investigators have demonstrated that initial uptake of the first bevacizumab biosimilar (Mvasi, Amgen) in the United States was strongest for patients receiving treatment for metastatic...
(Yahoo! Finance) Jan 17, 2021 - Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for...
(NASDAQ) Jan 18, 2021 - Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively.
(OBR) Jan 17, 2021 - Ivosidenib added nearly three months to the median overall survival of previously treated patients with advanced IDH1-mutated cholangiocarcinoma (CCA), compared with placebo, according to findings reported at the...
(OBR) Jan 17, 2021 - Preoperative neoadjuvant modified FOLFIRINOX is associated with favorable overall survival (OS) rates in patients with borderline resectable pancreatic cancer, relative to historical data. But combining this therapy...
Follow @OBRTweets